Insider Ledger
KLRS insider buying and SEC filings, explained
Kalaris Therapeutics, Inc. · CIK 1754068
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Allovir, Inc.; ViraCyte, Inc.
Insider activity in the last 12 months
Bought
$6.2M
Insiders who bought
1
Sold (not marked 10b5-1)
$13K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 20, 2026 | Purchase (code P) | Srinivas Akkaraju (Director and 10% owner) bought 244,300 shares indirectly (by entity) at $4.83 ($1.2M), reported as a purchase (code P). Holdings by entity up 12% to 2,224,147 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed May 22, 2026 |
| Mar 20, 2026 | Sale | Brett R Hagen (Chief Accounting Officer) sold 1,915 shares at $6.72 ($13K). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 23, 2026 |
| Dec 18, 2025 | Purchase (code P) | Srinivas Akkaraju (Director and 10% owner) bought 479,847 shares indirectly (by entity) at $10.42 ($5.0M), reported as a purchase (code P). Holdings by entity up 32% to 1,979,847 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Feb 17, 2026 |
16 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow KLRS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.